Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective.
Health-related quality of life
Ovarian cancer
PARP inhibitor
Statistical analysis
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
01
07
2022
pubmed:
28
7
2022
medline:
26
10
2022
entrez:
27
7
2022
Statut:
ppublish
Résumé
The poly (ADP-ribose) polymerase inhibitors (PARPi) have yielded significant clinical benefits as maintenance therapy in women with newly diagnosed and relapsed platinum-sensitive advanced ovarian cancer. These drugs were approved based on progression-free survival, the primary endpoint of their respective pivotal trials. Health-related quality of life (HRQoL) and/or patient-reported outcomes were included in these trials as a secondary exploratory endpoint. Nevertheless, many weaknesses in the analysis of HRQoL across these trials can be noticed. Heterogeneity and suboptimal HRQoL analysis in oncology trials contribute to misconceptions about this endpoint among oncologists and prevent quality of life as being an endpoint used for approvals. In this article, we discuss these HRQoL results from a methodological perspective and propose some solutions for improvement that could be used by regulatory and academic institutions running ovarian cancers trials. Notably, we suggest to measure and analyze HRQoL data after disease progression, to focus dedicated papers on the statistical analyses of HRQoL recommended by the SISAQOL consortium (linear mixed model for repeated measures and time-to-event approaches) and to communicate on available guidelines to ensure compliance with best international practices regarding the measurement and analysis of HRQoL.
Identifiants
pubmed: 35895164
doi: 10.1007/s11136-022-03193-0
pii: 10.1007/s11136-022-03193-0
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Ribose
681HV46001
Adenosine Diphosphate
61D2G4IYVH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3331-3337Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., et al. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495–2505.
doi: 10.1056/NEJMoa1810858
Poveda, A., Floquet, A., Ledermann, J.A., Asher, R., Penson, R.T., Oza, A.M., et al. (2021). Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA
doi: 10.1016/S1470-2045(21)00073-5
Friedlander, M., Moore, K. N., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., et al. (2021). Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): A randomised, phase 3 trial. The lancet Oncology, 22(5), 632–642.
doi: 10.1016/S1470-2045(21)00098-X
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., et al. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine, 381(25), 2416–2428.
doi: 10.1056/NEJMoa1911361
González-Martín, A., Pothuri, B., Vergote, I., DePont, C. R., Graybill, W., Mirza, M. R., et al. (2019). Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 381(25), 2391–2402.
doi: 10.1056/NEJMoa1910962
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., et al. (2016). Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. New England Journal of Medicine, 375(22), 2154–2164.
doi: 10.1056/NEJMoa1611310
Freyer, G., Pothuri, B., Han, S., Chase, D., Monk, B., Heitz, F., et al. (2020). 17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. International Journal of Gynecological Cancer, 30(Suppl 3), A12.
Pothuri, B., Han, S., Chase, D., Heitz, F., Burger, R., Gaba, L., et al. (2020). 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Annals of Oncology, 31, S612–S613.
doi: 10.1016/j.annonc.2020.08.949
Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., del Campo, J. M., et al. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): Results from a double-blind, phase 3, randomised controlled trial. The lancet Oncology, 19(8), 1117–1125.
doi: 10.1016/S1470-2045(18)30333-4
Matulonis, U. A., Walder, L., Nøttrup, T. J., Bessette, P., Mahner, S., Gil-Martin, M., et al. (2019). Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: A TWiST analysis of the ENGOT-OV16/NOVA trial. Journal of Clinical Oncology, 37(34), 3183–3191.
doi: 10.1200/JCO.19.00917
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., et al. (2017). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet., 390(10106), 1949–1961.
doi: 10.1016/S0140-6736(17)32440-6
Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., et al. (2020). Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma. Journal of Clinical Oncology, 38(30), 3494–3505.
doi: 10.1200/JCO.19.03107
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., et al. (2019). Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. New England Journal of Medicine, 381(25), 2403–2415.
doi: 10.1056/NEJMoa1909707
809MO Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel) + chemotherapy followed by vel maintenance (maint) - Annals of Oncology [Internet]. [cited 2022 Jan 4]. Available from: https://www.annalsofoncology.org/article/S0923-7534(20)40944-5/fulltext
Bonnetain, F., Fiteni, F., Efficace, F., & Anota, A. (2016). Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. Journal of Clinical Oncology, 34(16), 1953–1956.
doi: 10.1200/JCO.2014.56.7974
Clinical-Trial-Endpoints-Approval-Cancer-Drugs-Biologics-final-guidance.pdf.
Calvert, M., King, M., Mercieca-Bebber, R., Aiyegbusi, O., Kyte, D., Slade, A., et al. (2021). SPIRIT-PRO Extension explanation and elaboration: Guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. British Medical Journal Open, 11(6), e045105.
Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. The CONSORT PRO Extension. 2010; 9
Coens, C., Pe, M., Dueck, A. C., Sloan, J., Basch, E., Calvert, M., et al. (2020). International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: Recommendations of the SISAQOL Consortium. The Lancet Oncology, 21(2), e83-96.
doi: 10.1016/S1470-2045(19)30790-9
Chakraborty, R., Cannella, L., Cottone, F., & Efficace, F. (2020). Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: A systematic review. Lancet Haematology, 7(12), e892-901.
doi: 10.1016/S2352-3026(20)30292-1
Musoro, J. Z., Coens, C., Greimel, E., King, M. T., Sprangers, M. A. G., Nordin, A., et al. (2020). Minimally important differences for interpreting European organisation for research and treatment of cancer (EORTC) quality of life questionnaire core 30 scores in patients with ovarian cancer. Gynecologic Oncology, 159(2), 515–521.
doi: 10.1016/j.ygyno.2020.09.007